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Precision medicine is an approach to detecting, treating, and managing disease that is
based on individual variation in genetic, environmental, and lifestyle factors. Precision medi-
cine is expected to reduce health disparities, but this will be possible only if studies have
adequate representation of racial minorities.
Objective
It is critical to anticipate the rates at which individuals from diverse populations are likely to
participate in precision medicine studies as research initiatives are being developed. We
evaluated the likelihood of participating in a clinical study for precision medicine.
Design, Setting, Participants
Observational study conducted between October 2010 and February 2011 in a national
sample of African Americans.
Main OutcomeMeasure
Intentions to participate in a government sponsored study that involves providing a biospe-
cimen and generates data that could be shared with other researchers to conduct future
studies.
Results
One third of respondents would participate in a clinical study for precision medicine. Only
gender had a significant independent association with participation intentions. Men had a
1.86 (95% CI = 1.11, 3.12, p = 0.02) increased likelihood of participating in a precision
medicine study compared to women in the model that included overall barriers and facilita-
tors. In the model with specific participation barriers, distrust was associated with a
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Conclusion and Relevance
African Americans may have low enrollment in PMI research. As PMI research is imple-
mented, extensive efforts will be needed to ensure adequate representation. Additional
research is needed to identify optimal ways of ethically describing precision medicine stud-
ies to ensure sufficient recruitment of racial minorities.
Introduction
On January 20, 2015, a new precision medicine initiative (PMI) was announced by President
Barack Obama [1]. The long-term goal of the PMI is to develop and implement individualized
approaches to disease prevention and treatment based on genomic and molecular information
as well as environmental and lifestyle factors. To realize this goal, new research will be needed
to develop genomic approaches to medical care and to evaluate the effects of these strategies on
health care outcomes. A research cohort has been proposed to achieve the goals of PMI; this
cohort is likely to be based on participants previously enrolled in cohorts funded by the NIH
[1]. While this approach represents an efficient strategy for recruiting participants for new
PMI research, the racial and ethnic diversity of these cohorts will need to be examined carefully
to ensure that the individualized approaches developed through the PMI do not exacerbate dis-
parities in health outcomes. This is because racial and ethnic minorities are likely to be under-
represented in existing cohorts and biobanks established to support genomic research. Using
data from published genome wide association studies (GWAS), Haga found that 92% of partic-
ipants in GWAS research conducted in the United States were white and only 3% were African
American [2].
Research is now being conducted to identify and understand barriers and facilitators to
African American participation in genomics research; most recently, we examined these issues
within the context of cancer genetics research [3,4]. Our research demonstrates that African
Americans would consider the potential benefits to themselves, relatives, and community as
part of making a decision to participate in cancer genetics research, but concerns about exploi-
tation, distrust of researchers, and investigators' motives are also important to participation
decisions [3]. African Americans would also consider who has access to their personal informa-
tion and what would happen to these data when making a decision to participate in cancer
genetics research [3]. Despite these concerns, however, 73% of African Americans would par-
ticipate in a cancer genetics research study [5] and 23% would be very likely to donate a biospe-
cimens to a biobank [4]. But, the expectations that individuals have about what would happen
to their biospecimen were important to biobank donation intentions. Specifically, respondents
who had greater positive expectations about participating in cancer genetics research and
reported more participation facilitators relative to barriers were most likely to be willing to
donate to a biobank [4].
The expectations that individuals have about research are shaped by many factors that
include what potential participants are told about the procedures involved in participation and
how the study is described as part of obtaining informed consent. While prior studies have
examined barriers and facilitators to minority participation in medical research [6], the PMI is
a new initiative that is anticipated to have several unique features that include the creation of a
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national cohort that includes research subjects who have volunteered to provide genetic data,
donate biological samples, and contribute information about their lifestyle that is linked with
their electronic health record. This new model of conducting research raises several issues
related to the engagement of research volunteers, data sharing, and privacy; because of the
under-representation of racial minorities in genomic research [2], attention is now being given
to ensuring the racial and ethnic diversity of the PMI cohort [7]. For instance, if PMI cohorts
are established from existing studies, then the distribution of racial and ethnic minorities is
likely to reflect the diversity of established cohorts. Further, individuals being recruited to par-
ticipate in the PMI from established cohorts may have more positive expectations and be more
likely to participate in a new study, depending on their experiences in the original cohort. But,
African Americans are likely to be under-represented in existing cohorts [2]; therefore, they
may not be readily able to base expectations about participating in PMI studies on prior experi-
ences. For this reason, their decisions about participating in PMI research may be based on
how the study is described and the procedures involved in participation. To enhance the effi-
ciency of recruiting African Americans ethically into PMI studies, it is important to evaluate
their willingness to participate in genomic research based on how projects might be described.
Therefore, in this study, we examined the likelihood that African Americans would participate
in a clinical study that was methodologically similar to the cohort research that has been pro-
posed as part of PMI [1]. We were also interested in identifying variables that had a significant
independent association with participating in the clinical study that was described in the
vignette.
Materials and Methods
This study was reviewed and approved by the Institutional Review Board (IRB) at the Univer-
sity of Pennsylvania and was also reviewed and approved by the IRB at the Medical University
of South Carolina after the Principal Investigator (CHH) moved to this institution. Verbal
informed consent was obtained from all participants. Participants completed a telephone-
based survey, thus written consent was not obtained. Participant consent was recorded using a
screening questionnaire. We developed a research vignette that was based on findings from our
qualitative research on decision making about participating in cancer genetic research [3]. Spe-
cifically, the vignette asked respondents how likely it was that they would participate in a study
(1 = unlikely to 5 = very likely) that: (1) was sponsored by the government to provide informa-
tion about the health of African Americans, (2) participation involves answering a question-
naire and providing a cheek swab, (3) the data will be used for the current study and also may
be shared with other researchers to conduct future studies, (4) participants would not receive
any results. This was one of eight vignettes administered to African American adults enrolled
into a national survey study of attitudes about participating in cancer genetics research. Survey
details have been described previously [4] and this report includes 510 survey respondents
(34% of the total sample) who provided data on their willingness to participate in this research
vignette.
Measures
Our analysis was guided by findings from prior studies on African American participation in
genetics research [8–10] and our previous research on biobanking among African Americans
which has shown that distrust in health care providers, attitudes about genetics research, and
perceived barriers and facilitators to participating in research are associated with intentions to
donate biospecimens to a biobank [4]. Specifically, we measured attitudes about participating
in genetics research using items that asked respondents how much they agreed or disagreed
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(1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree) with statements
that assessed positive outcomes (e.g., the results would be used to help future generations, I
would get information about how to detect, prevent, and treat cancer that was just for me) and
negative outcomes related to privacy (e.g., my information would not be kept private), and
impact on health care and outcomes (e.g., the results would be used to develop cancer treat-
ment drugs that someone like me could not afford). We summed responses to these items so
that higher scores reflected greater expectations about positive and negative outcomes. The
Cronbach’s alpha for these scales were 0.5 for positive expectations, 0.65 for negative expecta-
tions about privacy, and 0.55 for negative expectations about the impact on health care and
outcomes in our previous research. To measure participation barriers and facilitators, respon-
dents were asked how much issues such as concerns about disclosure of personal information
(e.g., blood or saliva sample, medical history) and provision of free medication or health care
would affect their decision to participate in cancer genetics research (1 = very likely, 2 = some-
what likely, 3 = make no difference, 4 = somewhat unlikely, 5 = very unlikely). Responses of
‘somewhat or very unlikely’ were recoded as -1, responses of ‘make no difference’ were recoded
as 0, and responses of ‘somewhat or very likely’ were recoded as 1. We summed responses to
the recoded items to calculate a total score such that a negative score indicated greater barriers,
a positive score indicated greater facilitators, and a score of zero indicated an equal number of
barriers and facilitators. Forty-five percent of respondents reported more participation facilita-
tors, 9% of respondents had an equal number of barriers and facilitators, and 46% of respon-
dents reported more participation barriers. Lastly, we used the altruism scale to measure the
extent to which respondents were concerned about the needs and benefits to others relative to
their own [11]. Altruism items were as follows: (1) people should be willing to help others who
are less fortunate, (2) those in need have to learn to take care of themselves and not depend on
others, (3) personally assisting people in trouble is very important to me, (4) these days people
need to look after themselves and not overly worry about others. Items were summed so that
higher scores reflected greater altruism; the Cronbach’s alpha for the scale was 0.40.
Statistical Methods
First, descriptive statistics were generated to characterize respondents in terms of sociodemo-
graphic factors, attitudes about participating in genetics research, and participation barriers
and facilitators. Frequencies were also generated to characterize willingness to participate in
the study described in the research vignette. Next, we generated a multivariate logistic regres-
sion model to examine the independent associations between attitudes, barriers and facilitators,
and participation intentions. Since individuals may be unwilling to donate biospecimens and
personal health information to a biobank because of perceived barriers [4], we examined the
association between reasons that would make respondents most unlikely to participate and
intentions in a separate multivariate logistic regression model. Study data were weighted in
these analyses to account for phone service (landline or cellular) and population targets for
education, age, and gender using estimates from the March 2011 Current Population Survey.
Results
S1 Table shows the characteristics of the study sample. Overall, 31% of respondents reported
that it was very or somewhat likely that they would participate in a government-sponsored
study that involved answering a questionnaire and providing a cheek swab, the data would be
used for the current study and could also be shared with other researchers, and participants
would not receive any results. Sixty-nine percent of respondents reported that it was very/
somewhat unlikely or neutral that they would participate. As shown in S2 Table, there was
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high endorsement of items that measured positive expectations about participating in cancer
genetics research and lower endorsement of those that measured negative expectations. For
instance, 86% of respondents agreed that the results of would be used to help future generations
and 84% agreed that they would feel that they contributed to the development of better strate-
gies for detecting, preventing, and treating cancer. With respect to endorsement of items that
measured negative expectations about privacy, only 34% agreed that researchers would use the
results of the study to make profits and 16% agreed that their DNA would be tampered with.
The endorsement of items that measured negative expectations about the impact of participat-
ing in cancer genetics research was similar: 57% agreed that the results of the study would be
used to develop cancer treatment drugs that someone like them could not afford and 17%
agreed that researchers would be dishonest about the purpose of the study. S3 Table shows
descriptive information on reasons for participating in cancer genetics research. The most
important participation barriers, or reasons for not participating in studies, included: if respon-
dents did not know who would be able to obtain their personal information (60% unlikely to
participate), if it were hard to get to where the study was being conducted (63% unlikely to par-
ticipate), and if the findings from the study would not be made available (59% unlikely to
participate).
S4 Table reports the results of the multivariate logistic regression analyses. Only gender had
a significant independent association with the likelihood of participating in a PMI study in the
model that included overall participation barriers and facilitators. Compared to women, men
had 1.86 increased likelihood of participating in the PMI study (95% CI = 1.11, 3.12, p = 0.02).
No other sociodemographic factors had a significant association with the likelihood of partici-
pation. While respondents who were distrustful of researchers had a lower likelihood of partici-
pation compared to those who trusted investigators, this association was not statistically
significant (OR = 0.61, 95% CI = 0.36, 1.03, p = 0.06). Beliefs about positive expectations, con-
cerns about privacy, and negative expectations about the impact of genetic research did not
have significant associations with the likelihood of participation. The results of the logistic
regression model that included specific participation barriers were similar. Male gender had a
significant association with an increased likelihood of participation (OR = 1.85, 95% CI = 1.10,
3.10, p = 0.02) whereas distrust was associated with a reduced likelihood of participating in the
research described in the vignette (OR = 0.57, 95% CI = 0.34, 0.96, p = 0.04).
Discussion
As PMI research and cohorts are being developed, it is critical to anticipate the rates at which
individuals from diverse populations are likely to participate. Racial and ethnic minorities are
under-represented in genomics research [2]; their continued lack of participation in PMI stud-
ies will further exacerbate disparities in health care outcomes. Limited inclusion of racial and
ethnic minorities is likely to result in sample sizes that are too small to support the discovery of
genomic risk factors for disease and development of personalized therapeutic and prevention
strategies involving and relevant to these underrepresented groups. Data on participation
intentions allows investigators to anticipate the rates and which potential participants will pro-
vide informed consent for study enrollment. This data can also be used to project recruitment
costs. Our study is the first to examine the likelihood that African American adults would par-
ticipate in a government sponsored study that was methodologically similar to the cohort
study that has been described as an example of PMI research. Other studies have evaluated bar-
riers and facilitators to minority participation in medical research overall [6] and intentions to
participate in genetic research [4,5]. But, research on intentions to participate in genetic
research did not describe the procedures involved in participation, how study data would be
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used, nor indicate if results would be made available. This innovative aspect of our present
study extends previous research on participation intentions in an important way by providing
more contextual information about study procedures and the outcomes of enrolling in the
research. However, our research is not without some limitations, including the cross-sectional
collection of data on attitudes about participating in research, perceived barriers and facilitators
to participation, and participation intentions and the landline and cellular response rates of
31.8% and 26.8%, respectively. Even with diminishing response rates, however, the samples
enrolled in telephone surveys are likely to be similar to the US population in terms of sociode-
mographic characteristics [12]. Additional limitations may be that we measured participation
intentions rather than actual enrollment rates in a subset of survey respondents. This was
because specific PMI studies have not been developed and behavioral intentions are the best
predictor of actual behavior. Our previous research on genetic testing decisions among African
Americans suggests that intentions are a reasonable proxy for decision outcomes in this popu-
lation [13,14]. The terminology we used to describe the study in the research vignette may be
an additional limitation that may have generated a negative perception of the study described
in the scenario. Thus, as PMI studies are implemented, it will be important to examine actual
participation rates using longitudinal designs in which attitudes, barriers, and facilitators are
measured prospectively before enrollment decisions are made based on the terminology used
to describe studies as part of obtaining informed consent.
In contrast to prior studies that evaluated participation intentions in cancer genetics
research and biobanks [4,5], and research showing that 73% of African Americans actually pro-
vided consent to have biologic samples and DNA stored in the NHANES repository for genetic
research [15,16]; only about one-third of respondents in the present study would participate in
a study that is methodologically similar to the cohort proposed as part of PMI research [1].
Our vignette described a potential benefit to African Americans, but individuals may still have
privacy concerns that reduce participation in PMI research. In the present study, about one-
third of respondents endorsed concerns that researchers would share personal information
with others, information would not be kept private, and other individuals would be able to
access their DNA. The potential for data to be shared with other researchers was one element
in our research vignette; concerns about privacy may be activated in studies that involve shar-
ing personal and/or genomic information with other investigators. Another possible explana-
tion for the low participation intentions we found in the present study is because results from
the research would not be provided. Retention in a clinical genetics research study was lower
among African American women who did not receive a tangible benefit following study enroll-
ment (e.g., genetic counseling for BRCA1 and BRCA2 mutations) [17]. Not receiving personal
or research results may be a disincentive for participating in PMI among African Americans.
Although distrust has been shown to be a barrier to African American participation in clini-
cal research [18,19] and is also associated with a reduced willingness to donate biospecimens to
a biobank and participate in cancer genetics research [4], distrust did not have a significant
independent association with the likelihood of participating in a government sponsored study
that involved providing clinical data and biospecimens that would be used in the current study
and may also be shared with other researchers to conduct future studies in the model that
included overall participation barriers and facilitators. Altruistic values did not have a signifi-
cant association with participation intentions in the logistic regression model with overall par-
ticipation barriers and facilitators nor in the model that included specific participation barriers.
However, in the model that included specific barriers related to lack of access to the study site,
concern about who would be able to access personal health information, and not being pro-
vided with results from the study, distrust was associated with a significantly reduced likeli-
hood of participating in the study described in the vignette. Conceptually, distrust has been
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described as a barrier to accepting enrollment [20] whereas having difficulty getting to the
study site may reduce one’s opportunity to participate. Although the association was not statis-
tically significant, respondents who reported that having difficulty getting to where the study
was being conducted would make it unlikely that they would participate had a 50% lower likeli-
hood of participating in study described in our vignette. Previous research has shown that Afri-
can Americans who usually receive medical care from at a facility other than a doctor’s office
(e.g., community center) were more likely to be willing to donate a biospecimens to cancer
genetics research [5]. Our finding suggests that it may be important to include diverse types of
health care settings in the PMI in order to ensure that racial minorities have a sufficient oppor-
tunity to participate in this research.
In both logistic regression models, men had an 80% increased likelihood of participating in
the precision medicine study described in our vignette. African American men may be under-
represented in clinical research [21], but there are some examples of successful recruitment of
African American men in both genetic and non-genetic studies. Relative to women, African
American men had similar rates of participating in a lifestyle intervention that was designed to
increase motivation to change diet and physical activity [22]. Similarly, the African American
Hereditary Prostate Cancer (AAHPC) [23] study enrolled 92 African American high risk fami-
lies and complete clinical data were available on 154 African American men who had a per-
sonal history of prostate cancer [24]. Further, the Jackson Heart Study (JHS) enrolled 96% of
the targeted sample of African American men and women and participants were diverse in
terms of education, income, and employment characteristics [25]. The recruitment methods
used in the JHS were developed based on the participation barriers and facilitators identified in
research that was conducted prior to implementing study recruitment [25]. Common charac-
teristics of previous studies that have been successful in recruiting African American men is
that they examined participation barriers and facilitators prior to implementing recruitment
activities, developed the study to demonstrate specific benefits to participation, and collabo-
rated with diverse providers and organizations to implement recruitment [26–29]. Additional
research is needed to develop a better understanding of the reasons why African American
men would be willing to participate in PMI research and to translate this information into
recruitment messages and strategies to increase the likelihood of enrollment. Although atti-
tudes about participating in genetics research did not have a significant independent associa-
tion with intentions to participate in a PMI study in the present report, these beliefs have been
associated with intentions to donate biospecimens to a biobank [4]. In other research, we
found that respondents who had greater participation facilitators relative to barriers were
about twice as likely as those who had more participation barriers to participate in the genomic
study described in our vignette.
A long-term goal for PMI is to develop a new model for conducting research that engages
participants, shares data responsibly, and ensures privacy [30]. There is a growing body of
research on barriers and facilitators to enrollment in cancer genetics research; our findings
shed new light about how African Americans are likely to respond to an invitation to partici-
pate in PMI research. There was considerable variability in positive and negative expectations
about participating in genetics research among respondents in the present study and the most
important participation barriers included lack of access to the study site, concern about who
would be able to access personal health information, and not being provided with results from
the study. These issues can be addressed as part of efforts to develop precision medicine initia-
tives by including diverse types of health care settings as study sites and developing policies
and procedures for data sharing and return of results that address the privacy concerns and
preferences for research information among potential research participants. Given participa-
tion intentions did not vary among respondents based on their sociodemographic background
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or attitudes about participating in research, the way in which precision medicine studies are
described to potential participants may be an important factor in participation decisions
among African Americans. Additional research is needed to compare intentions to participate
in genomic research that are described as having different objectives, benefits, and outcomes in
order to determine the optimal ways to describe PMI studies to potential participants. These
studies should also compare racial differences in responses to alternate research descriptions
and determine if different factors are associated with the likelihood of participation among
diverse groups. In addition to developing community and clinical partnerships to enhance
PMI research, findings from the studies described above can be used to develop methods that
enhance recruitment outcomes in racially and ethnically diverse group ethically. This form of
research is critical. As PMI research becomes a national focus for improving prevention and
treatment on an individual basis, a lack of representation of racial and ethnic minorities may
limit the development of individualized strategies with populations that already experience a
higher burden of chronic diseases and worse health care outcomes.
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